Study links GLP-1 weight-loss drugs to rare vitamin B1 deficiency causing Wernicke encephalopathy
Solo los hechos

Study links GLP-1 weight-loss drugs to rare vitamin B1 deficiency causing Wernicke encephalopathy

Resumen

Researchers identified 15 cases of Wernicke encephalopathy in 2023-2024 among patients using GLP-1 agonists, highlighting a potential risk of severe thiamine deficiency.

A recent analysis identified 15 reported instances of Wernicke encephalopathy, a neurological disorder caused by severe thiamine (vitamin B1) deficiency, in individuals using GLP-1 receptor agonists such as semaglutide and tirzepatide. The cases, recorded in 2023 and 2024, involved patients taking medications marketed for weight management, including Ozempic, Wegovy, Mounjaro and Zepbound.

Wernicke encephalopathy can produce confusion, impaired coordination, balance problems and abnormal eye movements, and may result in permanent brain injury or death if not treated promptly. The condition is considered a medical emergency.

The study noted that most affected patients experienced significant vomiting, loss of appetite, poor nutrition or rapid weight loss, which can reduce intake of thiamine-rich foods such as pork, fish and whole grains. Researchers said the findings underscore the need for clinicians to inform patients about the risk and to monitor for early symptoms.

"Physicians should be aware of the potential for severe vitamin B1 deficiency in patients on GLP-1 therapies and counsel them on nutritional adequacy," a study co-author said.

Sigue leyendo, gratis

Crea una cuenta gratis para seguir las noticias. No se requiere tarjeta.